移植后外周血供者特异性干扰素-γ酶联免疫斑点试验区分肾移植受者亚临床排斥与新发供者特异性同种抗体的风险
该研究在60例肾移植患者横断面队列中发现,供者特异性IFN-γ ELISPOT阴性可准确排除亚临床T细胞介导性排斥;在101例前瞻性队列中验证,移植后3个月和6个月的ELISPOT结果可独立区分6个月时亚临床T细胞介导性排斥(OR 0.072,95%CI 0.008-0.653),并独立关联后续显著抗供者HLA抗体产生(OR 0.085,95%CI 0.008-0.862)及更差的2年移植肾功能。
要点
- 供者特异性IFN-γ ELISPOT阴性可准确排除亚临床T细胞介导性排斥。
- 移植后3个月和6个月ELISPOT结果独立区分6个月时亚临床T细胞介导性排斥(OR 0.072)。
- ELISPOT结果独立关联后续显著抗供者HLA抗体产生及更差的2年移植肾功能。
核心结论
- 移植后供者特异性IFN-γ ELISPOT免疫监测可评估亚临床T细胞介导性排斥和抗供者HLA抗体的发生风险,可能减少监测性活检的需求。
- 该研究为个体化免疫抑制以改善移植后结局提供了指导。
研究设计与样本
- 初始横断面队列纳入60例肾移植患者,均接受6个月监测性活检。
- 另设独立前瞻性队列纳入101例患者进行验证,检测移植后3个月和6个月的供者特异性IFN-γ ELISPOT结果。
主要发现
- 初始横断面队列中,供者特异性IFN-γ ELISPOT阴性可准确排除亚临床T细胞介导性排斥。
- 前瞻性验证队列中,移植后3个月和6个月的ELISPOT结果显著区分6个月时亚临床T细胞介导性排斥,独立于其他临床变量(OR 0.072,95%CI 0.008-0.653)。
- 移植后供者特异性IFN-γ ELISPOT结果独立关联后续显著抗供者HLA抗体产生(OR 0.085,95%CI 0.008-0.862)。
- 与ELISPOT阴性患者相比,ELISPOT阳性患者2年移植肾功能(估算肾小球滤过率)显著更差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Noninvasive diagnosis of kidney allograft inflammation in transplant recipients with stable graft function (subclinical rejection) could permit more effective therapy and prevent later development of de novo anti-donor HLA antibodies and/or graft dysfunction. Here we tested whether quantifying posttransplant donor-specific alloreactive T-cells by IFN-γ ELISPOT assay noninvasively detects subclinical T-cell mediated rejection and/or predicts development of anti-donor HLA antibodies. Using an initial cross-sectional cohort of 60 kidney transplant patients with six-month surveillance biopsies, we found that negative donor-specific IFN-γ ELISPOT assays accurately ruled out the presence of subclinical T-cell mediated rejection. These results were validated using a distinct prospective cohort of 101 patients where donor-specific IFN-γ ELISPOT results at both three- and six-months posttransplant significantly differentiated patients with subclinical T-cell mediated rejection at six months, independent of other clinical variables (odds ratio 0.072, 95% confidence interval 0.008-0.653). The posttransplant donor-specific IFN-γ ELISPOT results independently associated with subsequent development of significant anti-donor HLA antibodies (0.085, 0.008-0.862) and with significantly worse two-year function (estimated glomerular filtration rate) compared to patients with a negative test. Thus, posttransplant immune monitoring by donor-specific IFN-γ ELISPOT can assess risk for developing subclinical T-cell mediated rejection and anti-donor HLA antibodies, potentially limiting the need for surveillance biopsies. Our study provides a guide for individualizing immunosuppression to improve posttransplant outcomes.
引用
- Crespo E, Cravedi P, Martorell J, et al. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients. Kidney Int. 2017. PMID: 28274484. doi:10.1016/j.kint.2016.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。